Amplia Therapeutics (ASX:ATX) enrolled 53 patients with pancreatic cancer for its ACCENT Phase 2a clinical trial, completing recruitment two months ahead of schedule, according to a Friday Australian bourse filing.
The two-stage trial explores the use of Amplia's focal adhesion kinase inhibitor narmafotinib in combination with chemotherapy in first-line patients with advanced pancreatic cancer.
The first stage of the trial identified a safe and tolerated daily oral dose of narmafotinib. It was completed in November 2023.
The second stage will explore the efficacy of the safe dose of narmafotinib. Preliminary safety, tolerability, and efficacy data were earlier reported for the initial 26 patients.
It reported a 38.5% objective response rate from the second stage, exceeding historical benchmarks. It also reported a median trial duration of 197 days for the first 26 patient groups, indicating a 68% improvement over historical data of 117 days.
The total number of patients remaining in the study is 35.
The firm's shares rose over 7% on market close on Thursday.
免责声明：投资有风险，本文并非投资建议，以上内容不应被视为任何金融产品的购买或出售要约、建议或邀请，作者或其他用户的任何相关讨论、评论或帖子也不应被视为此类内容。本文仅供一般参考，不考虑您的个人投资目标、财务状况或需求。TTM对信息的准确性和完整性不承担任何责任或保证，投资者应自行研究并在投资前寻求专业建议。